Metabolic Effects of Natriuretic Peptide Hormones

• Status: Active, not recruiting
• Trial end date: 2023-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Accumulating evidence suggests that the natriuretic peptide (NP) hormonal system has important effects on metabolism. However, more information is needed to better understand the effects of NPs on metabolism in humans. Therefore, the investigators propose a study to determine the effects of b-type natriuretic peptide (BNP) on energy and fat metabolism in humans. The investigators' primary hypothesis is that the administration of BNP will increase energy expenditure in humans. The investigators' secondary hypothesis is that BNP administration will promote changes in gene expression in fat tissue suggestive of fat "beiging" in humans. Interventions that safely increase energy expenditure and promote fat "beiging" represent potential strategies for treating metabolic dysfunction due to obesity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: VA Office of Research and Development
• Treatments: Hormones; Natriuretic Peptide, Brain

Criteria

Inclusion Criteria:

• Men and women ages 18-40 years

• Body Mass Index (BMI): 18.5 BMI<25 kg/m2 (lean) or BMI > or = 30 kg/m2 (obese)

Exclusion Criteria:

• Significant cardiovascular disease (including heart failure and atrial fibrillation)

• Significant pulmonary, liver, or renal disease

• Diabetes Mellitus

• Significant Hypertension

• Hypotension

• Thyroid dysfunction

• Active malignancy

• Current or recent use of glucocorticoids

• Current use of antihypertensive medications, including diuretics

• Current use of medications affecting glucose metabolism, including metformin

• Current use of amphetamines or other medications known to affect energy homeostasis

• Currently pregnant or breastfeeding, or unwilling to avoid becoming pregnant or breastfeeding during study duration

• Significant claustrophobia that would prevent the use of the metabolic cart as part of the study protocol

• Currently abnormal serum or plasma sodium or potassium level

• Known hypersensitivity to recombinant human b-type natriuretic peptide, BNP(1-32) (nesiritide), or phenylephrine

• Hemoglobin A1c (HbA1c) >= 6.5%

• Liver Function Tests (LFTs) elevated >2x upper limit of normal

• Estimated Glomerular Filtration Rate (eGFR) <60 ml/min

• Currently abnormal thyroid stimulating hormone (TSH)